Thomas Jefferson University

Jefferson Digital Commons
Department of Medicine Faculty Papers

Department of Medicine

January 2006

Clinical perspectives of emerging pathogens in bleeding disorders
Jamie Siegel
Thomas Jefferson University Hospital, Cardeza Foundation for Hematologic Research

Follow this and additional works at: https://jdc.jefferson.edu/medfp
Part of the Medical Genetics Commons

Let us know how access to this document benefits you
Recommended Citation
Siegel, Jamie, "Clinical perspectives of emerging pathogens in bleeding disorders" (2006).
Department of Medicine Faculty Papers. Paper 3.
https://jdc.jefferson.edu/medfp/3
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Clinical Perspectives of Emerging Pathogens in
Bleeding Disorders
Christopher A Ludlam, William G Powderly, Samuel Bozzette, Michael Diamond,
Marion A Koerper, Roshni Kulkarni, Bruce Ritchie, Jamie Siegel, Peter Simmonds,
Samuel Stanley, Michael L Tapper, Mario von Depka
University of Edinburgh, UK (Prof C A Ludlam FRCP, Prof P Simmonds FRCPath); University College
Dublin, Dublin, Ireland (Prof W G Powderly FRCPI); University of California San Diego, San Diego, CA,
USA (Prof S Bozzette MD); Washington University, St Louis, MO, USA (M Diamond MD, Prof S Stanley
MD); University of California San Francisco, San Francisco, CA, USA (M A Koerper MD); Michigan State
University, East Lansing, MI, USA (R Kulkarni MD); University of Alberta, Edmonton, AB, Canada (B
Ritchie MD); Thomas Jefferson University Hospital, Philadelphia, PA, USA (J Siegel MD); Lenox Hill
Hospital, New York, NY, USA (M L Tapper MD); and Medical University Hannover, Hannover, Germany
(Prof M von Depka MD)
Correspondence to:
Prof Christopher A Ludlam, Department of Clinical and Laboratory Haematology
Royal Infirmary, Edinburgh EH16 4SA, UK
Christopher.Ludlam@ed.ac.uk
As a result of immunological and nucleic-acid screening of plasma donations for transfusiontransmissible viruses, and the incorporation of viral reduction processes during plasma
fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many
known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell
lymphotropic virus. However, emerging pathogens could pose future threats, particularly
those with blood-borne stages that are resistant to viral-inactivation steps in the
manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better
understanding of infectious diseases allows challenges from newly described agents of
potential concern in the future to be anticipated, but the processes of zoonotic transmission
and genetic selection or modification ensure that plasma-derived products will continue to
be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the
issue of emerging infectious agents by developing recombinant products that limit the need
for human plasma during production. Such recombinant products have extended the safety
profile of their predecessors by ensuring that all reagents used for cell culture, purification
steps, and stabilisation and storage buffers are completely independent of human plasma.

Emerging pathogens could pose a substantial threat to recipients of therapeutic
coagulation-factor concentrates (CFC), as shown by the devastating effect of HIV on
patients who received these agents. The safety of CFC has improved greatly since their
introduction, and the risk of infectious diseases caused by plasma-derived preparations
is now very small. However, everyone concerned with haemophilia, including various
scientific and medical advisory committees, agrees that vigilance must be maintained to
ensure that new and unpredictable emerging blood-borne pathogens will not again
1–3
compromise the safety of CFC in the future. The risk of transmission of infectious
agents by a fresh blood component is very different from that for CFC because there
might not be an effective pathogen inactivation or removal step in the preparation
process, and the dose of infectious agent could be much higher than in CFC. The
special danger of contamination of CFC with pathogens is that a single batch could be
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used to treat, and possibly infect, hundreds of patients, as happened with HIV. The
pathogens discussed in this review are all potentially transmissible by fresh blood
products. The susceptibility to individual pathogens in fresh blood products in a
particular community will depend on the local epidemiology of the infectious agent. By
contrast, CFC commonly cross continents from site of plasma collection and
fractionation to use in recipients in a community with little experience of the agent. This
review focuses on the potential for emerging risks of infectious agents in CFC because
an essential public-health objective is to prevent epidemics of serious viral infections in
patients with haemophilia and others who depend exclusively on CFC for their wellbeing.
Search strategy and selection criteria
The references were selected by the authors from their
knowledge of published work.
The review is a summary of an interdisciplinary forum of clinicians who treat
haemophilia, infectious-disease specialists, and epidemiologists that was convened at
Washington University School of Medicine in St Louis, MO, USA, in June, 2004, to
discuss infectious-disease risk management in patients with haemophilia. The forum
had the following objectives: to review emerging blood-borne pathogens and their
potential effects on therapeutic CFC; to discuss clinical issues related to viral infections
in patients with haemophilia; and to review the safety of CFC in terms of transfusiontransmissible infections.

Emergence of new human pathogens
The National Academy of Sciences defines an emerging infection as one that is newly
identified, re-emerging, or drug resistant, with an incidence in people that has
increased within the previous two decades or is threatening to increase in the near
future.4 The first step of emergence, known as introduction, occurs when a previously
unknown pathogen comes into contact with a new host population, or when an
established pathogen changes its normal interaction pattern with its host population in
some crucial way to increase in prevalence. In the second step, known as adaptation,
the emerging agent becomes established and disseminates within the host population.
The factors that contribute to this process are complex; they include microbial
adaptation, advances in technology and industry, international travel and commerce,
the breakdown of public-health measures, economic development and increased land
use, changes in human demographics and behaviour, and war and famine.4
The introduction of a new pathogen into a previously unexposed population typically
occurs by interspecies, or zoonotic, transmission. For example, genetic analyses have
suggested that HIV infection was transmitted to human beings from a common
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subspecies of chimpanzee (Pan troglodytes troglodytes).5 Another well-publicised
example of zoonotic transmission is severe acute respiratory syndrome, caused by the
transmission of a new coronavirus to people, initially in southern China and probably
from small mammals, which are the natural hosts of the severe-acute-respiratorysyndrome coronavirus.6 After the virus first appeared in human beings, there was an
explosive short epidemic. Since clinical symptoms preceded the peak of transmission of
this virus, outbreaks were restricted by quarantine measures in China, Canada, and
other countries. Many epidemiologists predict similar types of outbreaks in the future
with emerging viruses.
A less widely known case of zoonotic transmission is of Nipah virus, a henipavirus that
causes potentially lethal encephalitis. The natural host is the flying fox (fruit bat); crossspecies transmission of the virus to animals occurred in southeast Asia where farmers
inhabited areas that had been cleared of forests, inadvertently exposing their livestock
to flying-fox habitats.7,8 In the late 1990s, there were several outbreaks of Nipah-virus
infection in pigs, with subsequent transmission of the virus to human beings. In
Malaysia, of 265 people infected during an outbreak of Nipah-virus infection, 105 died,
a mortality rate of 40%.9 Two other outbreaks of Nipah-virus infection have since
occurred in Bangladesh.7,8 The mortality rate among infected individuals approached
70% in the Bangladeshi outbreaks, and in contrast to the Malaysian outbreaks, the
virus might have been transmitted from one person to another. Hendra virus, a type of
henipavirus, causes disease in horses and was reported to be transmitted via exposure
to secretions from an infected racehorse to its trainer. The transmission vector remains
unknown but could be an arthropod.10
Any new viral pathogen poised to infect human beings must breach the natural barriers
to zoonotic transmission that exist at the levels of cellular entry and viral expression.
New emergent viruses might therefore have to acquire genetic mutations before active
propagation within people is possible. Some RNA viruses have mutation rates as high as
one nucleotide per 10 000 copied and therefore could be especially likely candidates for
zoonotic transmission.11 However, the evolution of a potentially large number of
adaptive mutations that enable productive replication and efficient continuing
transmission in a new host is rare, which might help to explain the low frequency of
emerging agents. However, when an emerging pathogen does succeed in adapting to a
new host species, the outcome can have a worldwide effect. New pathogens are also
more likely to emerge in conjunction with opportunistic infections in highly
immunosuppressed individuals, such as those with congenital immune defects, cancer,
or AIDS.12 Immunosuppression, especially in xenotransplantation settings, might enable
a poorly adapted virus to replicate and adapt to human beings and act as a bridge to
subsequent infection of the healthy population.13,14
These issues apply to infectious agents entering a new host population, but any preexisting aetiological agent for which the incidence has increased within the previous two
decades is also defined as an emerging pathogen. In many cases, an increase in
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incidence reflects a change in the interaction between host and vector, such as that
caused by extraordinary changes in ecosystems.15 For example, Rift Valley fever was
the ultimate cause of a cumulative 200,000 deaths after construction of the Aswan Dam
on the River Nile in Egypt in the 1960s created conditions in which the arthropod vector
flourished.16 Guanarito arenavirus emerged in Venezuela after forest clearing disrupted
the local ecology.17 This viral pathogen can be transmitted from rats to human beings,
in whom it causes haemorrhagic fever and can pose a threat to the blood supply. As
more people congregate within mega-cities, especially those of less developed countries
with less advanced hygiene systems, more emerging infectious agents that arise by
disruption of ecosystems can be expected.
After introduction and adaptation, the final step in pathogen emergence is the
dissemination of the emerging infectious agent within the host population. This step
can occur with an explosive short outbreak, such as that observed for the Ebola virus or
the coronavirus associated with severe acute respiratory syndrome. Alternatively, the
agent can propagate and spread via a slower and more insidious mechanism, such as
that observed with HIV.

Panel: Viruses
CPV
FPLV
HBV
HCV
HIV
HTLV
JEV
PCV
SLE
TTMV
TTV
WNV
YFV

Canine parvovirus
Feline panleucopenia virus
Hepatitis B virus
Hepatitis C virus
Human immunodeficiency virus
Human T-cell lymphotropic virus
Japanese encephalitis virus
Porcine circovirus
St Louis encephalitis virus
Torque-tenominivirus
Torque-tenovirus
West Nile virus
Yellow-fever virus

Potential threats to blood and blood products
Many infectious agents transmissible by blood transfusion are characterised by a longlasting and silent carrier state in which the pathogen circulates in the blood without
causing noticeable symptoms.18 Blood collected during this phase can be highly
infective, even though the donor has no symptoms. Agents that meet these criteria
include hepatitis B and C viruses (HBV and HCV), HIV, human T-cell lymphotropic
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viruses (HTLV) I and II, and West Nile virus (WNV).19 Because there is routine
screening for these agents, blood and blood products are generally thought to be safe
from these pathogens. However, many other viruses, for which donated blood is not
routinely screened, are known to produce a viraemic phase in the infected individual.
(Viruses for which we use an abbreviated name in this review are listed in the panel.)
Lipid-enveloped viruses
Flaviviruses, which are small, lipid-enveloped, positive-stranded RNA viruses, are a
subfamily of arthropod-borne viruses (arboviruses) that cycle between insect and
vertebrate hosts. At least 40 species are associated with human disease, including
WNV, dengue virus, St Louis encephalitis virus (SLE), yellow-fever virus (YFV), and
Japanese encephalitis virus (JEV).20,21 Human beings are the primary host for dengue
virus and YFV only. Arboviruses have a vast global distribution and show intriguing
emergence patterns based on ecological changes (figure 1).22 Because flaviviruses are
widespread and persistent in insect and animal populations and are so far resistant to
existing treatments, they pose a potential threat to the blood supply.

Figure 1:

Approximate global
distribution of
medically
important viruses in
the Japanese
encephalitis
serogroup of
flaviviruses.22

West Nile virus
This flavivirus is spread by mosquito vectors. The most important clinical phenotype of
non-lethal infection is meningoencephalitis.23 The virus first emerged during a 1999
outbreak in New York City, resulting in 62 confirmed cases and 22 deaths.24–26 During
2000 and 2001, similar numbers of human cases were noted in the eastern USA, and
evidence of WNV found in birds, farm animals, and mosquito pools showed that the
virus had spread over the whole eastern coast and had begun to spread westward. In
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2003, the US Centers for Disease Control and Prevention reported 9,862 cases of WNV
infection in 46 states and 264 associated deaths. The numbers were smaller in 2004,
with 2,470 reported cases in 41 states and 88 associated deaths. Infections have now
been recorded in some parts of Canada and Mexico. Currently, 2% to 3% of people in
certain areas of the USA are seropositive for WNV. The estimated risk, for example, of
transmission of the virus through transfusion during the 1999 epidemic in New York
was about 2.0 viraemic donations per 10 000 donors in the borough of Queens.27 The
risk varied greatly with time and location during 2002, reaching as high as 1.5 in 1000
donations.18 Of the 2.5 million blood donations screened for WNV from June to
December, 2003, 0.05% were positive at first screen, and 0.02% were confirmed.
Interventions to block transmission of WNV are hampered by the fact that 80% of cases
of infection are subclinical or asymptomatic. Since WNV is readily inactivated by low
pH, high temperature, and detergents, it is of less concern with plasma-protein-derived
CFC, for which these treatments are typically used during manufacturing.

Dengue fever and dengue haemorrhagic fever
Dengue virus is the most common arthropod-transmitted virus in the world and is an
important issue worldwide for the blood supply.28 Each year, there are 25 million to 100
million cases of dengue fever and 250,000 cases of dengue haemorrhagic fever
throughout the world.29 Dengue haemorrhagic fever or dengue shock syndrome has a
mortality rate of 10–40%, depending on the degree of access to high-quality tertiarycare facilities. Between 1980 and 1999, the number of cases of dengue virus in the
Americas increased by 50 times (figure 2).30 The primary mosquito vector for dengue
virus, Aedes aegypti, was almost eradicated from the USA after the DDT spraying
campaigns in the late 1950s but the population is now recovering.31 By comparison, in
Brazil there is an epidemic of dengue fever and dengue haemorrhagic fever, with an
estimated 500,000 to 1,000,000 cases per year. Other epidemics are occurring in
Central America, southeast Asia, and parts of Africa and Oceania. Worldwide, an
estimated 2.5 billion people are at risk. The infection has a viraemic phase that lasts 3–
5 days, and most cases remain subclinical. Since no screening tests are in place,
dengue virus might be expected to pose a future concern for the blood supply.

JEV
This virus is another important arbovirus threatening global blood supplies.32–34 It
causes severe encephalitis, and the mortality among patients admitted to hospital is
about 33%, with many survivors having long-term neurological sequelae. The heaviest
concentrations of infections are in southeast Asia and the Indian subcontinent. 20,000–
50,000 cases are reported every year in China alone.
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Figure 2: Reported cases of dengue fever in the Americas, 1980-99.30
Data for 1999 are provisional

Non-lipid-enveloped viruses
Viruses without lipid envelopes tend to be less susceptible than lipid-enveloped viruses
to inactivation methods because they are typically smaller in size and are likely to have
greater resistance to heat, irradiation, and solvent detergent treatment. Emerging nonlipid-enveloped viruses could therefore pose the greatest threat to plasma-derived CFC,
particularly in light of the recent outbreaks of infections with enteroviruses.35

Enteroviruses
These small non-lipid-enveloped viruses form a separate genus within the picornavirus
family. More than 70 serotypes have been isolated from people, including polioviruses,
coxsackieviruses, enterocytopathic human orphan viruses, and enteroviruses 68–71.
The normal site of replication for these viruses is the gastrointestinal tract; infection is
subclinical or results in a mild disorder in many cases. However, some of these viruses
can spread through the blood to other parts of the body, including the central nervous
system. The resulting diseases can be severe, partly depending on the specific
enterovirus serotype. Enteroviruses that undergo viraemic phases in their life cycle and
are associated with substantial morbidity (eg, enteroviruses 70 and 71) could be
particular threats to blood products.36–40 Enterovirus 70 was the causative agent of
epidemics of acute haemorrhagic conjunctivitis in Africa, Asia, India, and Europe
between 1969 and 1974. Enterovirus 71 seems to be highly pathogenic and
neurovirulent and has been associated with epidemics (eg, in Taiwan, Japan, and
Australia) of various acute diseases, including aseptic meningitis, encephalitis, paralytic
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poliomyelitis-like disease, hand-foot-and-mouth disease, herpangina, nonspecific febrile
illness, upper-respiratory-tract infection, enteritis, and viral exanthema.36–38 Enterovirus
infections can have a transient viraemic phase that precedes symptoms. This feature, in
combination with their resistance to inactivation, makes them a potential threat to the
blood and CFC supplies. In a study in Scotland, 0.024% of blood donations showed
evidence of enterovirus viraemia.41 This proportion predicts about 1,000 enteroviruscontaminated transfusions per year in the UK. A wide range of viral loads (figure 3) and
enterovirus serotypes were detected, including enterovirus 71, coxsackieviruses A2, A5,
A10, A16, B2, B3, B4, and B5, and echoviruses 11, 13, 18, and 30. In the light of the
numbers of potential infected donations, initiation of screening methods for
enteroviruses might be prudent to exclude the possibility of blood-transfusionassociated transmission of potentially pathogenic variants such as enteroviruses 70 and
71.

Figure 3:

Reported viral loads of
enterovirus types in Scottish
donor plasma.41

Circoviruses
These viruses are the smallest known mammalian nonlipid-enveloped viruses (18–28
nm) and are distributed ubiquitously among human beings and other mammals.42
Human circoviruses include torque-tenovirus (TTV) and torque-tenominivirus (TTMV),
two related viruses with highly divergent sequences. Each has a vast number of distinct
genotypes. Infected people seem to be viraemic with a wide range of genotypes of both
viruses, and viral loads are constantly high. Importantly for blood products, these
extremely small and stable non-lipid-enveloped viruses cannot be removed easily by
nanofiltration and as with other circoviruses important in veterinary medicine, such as
porcine circovirus (PCV), they are likely to be highly resistant to heat and other viral
inactivation protocols used in manufacture of blood products. There are no known
human diseases associated with circoviruses, but some features suggest that caution is
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warranted. These viruses have been associated with clinical disease in other species;
infection with PCV2 is the most commercially important disease in pigs today, leading to
multisystemic wasting syndrome.43 The virus is the cause of 15% of deaths in pigs, and
it has already jumped species to cattle and sheep. Chicken anaemia virus, an avian
circovirus, has been transmitted through contaminated manufactured livestock feed, a
further indication of the resistance to inactivation of these viruses. In human beings,
transmission of circoviruses to neonates can be associated with upper-respiratory-tract
infection.44 Since these viruses might maintain their continuously viraemic but
asymptomatic state in human beings through some immunosuppressive function, there
is a theoretical concern that they might also suppress the immune response to other
infectious agents.

Parvoviruses
Interspecies jumping is one of the primary routes by which new emerging pathogens
enter the human population. The parvovirus feline panleucopenia virus (FPLV) might
therefore constitute a future threat to people because of its ability to cross mammalian
barriers. It is a small non-lipid-enveloped virus that typically infects cats, mink,
raccoons, Arctic foxes, and raccoon dogs. In 1978, a new pathogenic variant emerged
in dogs and became known as canine parvovirus (CPV),45 which causes hyperthermia,
vomiting, diarrhoea, leucopenia, dyspnoea, myocarditis, pneumonitis, and in some
cases, virus-induced encephalitis.46,47 FPLV took about a decade to assume its new host
range.48,49 One of the first changes that differentiated CPV from FPLV and other animal
viruses was in the haemagglutinin molecule. Since then, strains of CPV have undergone
a series of changes, presumably in response to evolutionary selection, which resulted in
the global distribution of new variants.48 New antigenic variants (CPV2 types, including
2a, followed by 2b then 2c) have been isolated from cats and dogs in Japan and Brazil,
which suggests that interspecies transmission, and presumably genetic conversion,
continues.50–52 Host adaptation of CPV in canines suggests the possibility of similar
cross-species transmission, followed by adaptation in human beings.52 This potential
development could be accelerated by the close contact between dogs and people
throughout the world. Because they are small, resistant, non-lipid-enveloped viruses,
such emerging parvoviruses could pose a substantial future threat to blood and blood
products.
Polyomaviruses
Polyomaviruses, a genus of the larger papovavirus family, are small non-lipid-enveloped
viruses that might also pose a future risk to blood products. Two viruses, both of which
were isolated in 1971, are of particular interest. JC virus was first isolated from the
brain of a patient with Hodgkin’s disease who subsequently developed progressive
multifocal leucoencephalopathy. BK virus was first isolated from a susceptible
immunosuppressed patient who had recently received a kidney transplant. The main
site in the body found to harbour these viruses is the kidney. Lymphoid tissues,
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including bone marrow and spleen, have also been identified as sites of potential viral
latency.53–55 Both viruses have also been found in brain tumours.56
BK virus causes mild upper-respiratory-tract symptoms, occasional pyrexia, and
transient cystitis in immunocompetent individuals. In immunocompromised patients, the
infection is predominantly associated with diseases of the urogenital tract, particularly
haemorrhagic cystitis.54 Nephropathy associated with BK virus is emerging as an
important cause of renal dysfunction and loss of transplanted kidneys; the frequency of
infection with BK virus in transplant recipients is 5%.57,58 Perhaps of greater concern,
nucleic-acid sequences from the virus have been reported to persist in mononuclear
cells of healthy blood donors. Thus, of 231 individuals tested in a study in two different
centres, 29% were positive for BK virus sequences.54
Clinical infection with JC virus is generally found in association with long-term
immunosuppression and other chronic diseases, including AIDS, lympho-proliferative
diseases such as Hodgkin’s disease and chronic lymphocytic leukaemia, sarcoidosis,
tuberculosis, and systemic lupus erythematosus. JC virus causes chronic
meningoencephalitis and is associated with progressive multifocal leucoencephalopathy,
a fatal demyelinating disease of the central nervous system. Typically, the course of
progressive multifocal leucoencephalopathy is gradual, with initial impairment of
cognitive function, speech, vision, and movement. As it progresses, the pathology
accelerates, and patients develop more severe disabilities, including dementia,
paralysis, blindness, then coma, followed by death. The frequency of progressive
multifocal leucoencephalopathy increased with the AIDS pandemic, but now, with
effective antiretroviral therapy, HIV-infected patients rarely develop this disorder.51,52
Shedding of JC virus (and BK virus) in urine is significantly more common in HIVinfected patients than in non-HIV-infected individuals.59 Progressive multifocal
leucoencephalopathy is rare in children and young adults and is more common in
people in their 50s and 60s; this feature suggests that reactivation of latent virus, and
not primary infection, is the cause of viral disease.
Prions
Prions are self-replicating proteins implicated in transmissible spongiform
encephalopathies in people and animals. The prion protein in its physiological form,
PrPc, is a normal membrane constituent. Its function is uncertain, although it might be
involved in synaptic transmission or copper metabolism. The protein can undergo
conformational change to a pathological form in which it is protease-resistant (PrPres)
and it might also have altered glycosylation. This conformational change increases the
protein’s ability to aggregate. This form is the agent that causes transmissible
spongiform encephalopathies.
The most worrying manifestation of transmissible spongiform encephalopathies for
people is variant Creutzfeldt-Jakob disease, which was first recognised in 1996.60 The
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disease is caused by an infectious prion similar to that which causes bovine spongiform
encephalopathy and is transmitted by consumption of contaminated tissue from bovine
sources. The prion that causes variant Creutzfeldt-Jakob disease is found in lymphoid
tissue, in contrast to cases of the classic disease, and it therefore presents a potential
risk of infection through blood and plasma-derived blood products.61

Figure 4:

Quantification of PrPc
protein in fractionated
human blood.62

Several studies have shown that prions can be transmitted through blood. In one study,
68% of PrPc quantified in normal blood samples was in the plasma compartment, which
highlights the potential for similar distributions of infectious prion. Leucocyte depletion
alone might be insufficient to prevent transmission of PrPres (figure 4).62 Furthermore,
sheep experimentally infected with the infectious prion associated with bovine
spongiform encephalopathy or scrapie transmitted the encephalopathies to unexposed
sheep at a rate of 10–20% after whole-blood donations. Finally, two human cases of
probable transmission of the prion associated with variant Creutzfeldt-Jakob disease by
blood from donors who subsequently developed the disorder have been reported. In
the first case, the recipient received a transfusion in 1996, developed a neurological
disorder in 2002, and died 13 months after the onset of symptoms. At autopsy,
characteristic spongiform change was seen in the brain.63 The second patient died 5
years after a blood transfusion from a donor who subsequently developed variant
Creutzfeldt-Jakob disease. At autopsy, however, PrPres was found in the spleen and
cervical lymph nodes, but there was no spongiform histological change or PrPres in the
brain.64
At present, variant Creutzfeldt-Jakob disease from infected blood donors poses mainly a
theoretical risk to plasma-derived coagulation factors.65 The risk could be less than that
associated with fresh blood components because the pathogenic prion will be diluted in
the starting plasma pool and because it is partly excluded by the differential protein
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fractionation process from the final CFC.66 More highly purified CFC would probably
carry a lower risk of prion transmission. However, without a reliable diagnostic test for
prions, some concern about these agents will remain. In September, 2004, serious
concerns prompted the UK Departments of Health to issue letters to 6000 recipients of
products manufactured from UK plasma, warning them that there was a possibility of
transmission of variant Creutzfeldt-Jakob disease.
Public-health response
Regulatory bodies track adverse outcomes from the use of blood products, and publichealth agencies track infectious disease, but surveillance for infectious agents in the
blood supply is at an early stage and is not always done efficiently. Effective
surveillance of blood products requires a coordinated effort by regulatory bodies,
manufacturers, and treaters. Regulatory bodies must mandate effective postmarketing
surveillance. Manufacturers must use their global reach to identify rare adverse events,
and treaters must report adverse events as in the system established by UK
Haemophilia Doctors’ Organisation. Machine-readable labels such as those with bar
codes, electronic health-record databases that track clinical outcomes, and consented
tissue archives such as those of the US Centers for Disease Control and Prevention and
the Blood Borne Pathogens Surveillance Project of the Association of Hemophilia Centre
Directors of Canada are key tools for effective and efficient surveillance.67 Table 1 lists
some of these organisations.
Current clinical topics: viral disease in patients with haemophilia
Individuals with haemophilia and their physicians are particularly concerned about
emerging blood-borne infectious diseases because the patients are continually exposed
to blood and blood-derived products. The problems associated with HIV provide an
example of the dangers faced by these people. HIV contamination of the blood supply
was first recognised in 1983, although the first US case of HIV infection is now known
to have occurred in 1975. By 1985, 74% of patients using factor VIII were
seropositive.68,69 This degree of infection has had a profound effect on mortality among
haemophilic patients. The median age at death among patients with haemophilia A
decreased from 57 years before the HIV epidemic to 35 years in 1995, after the
epidemic had grown to enormous proportions. By comparison, the median lifespan for
HIV-negative haemophiliacs was 67 years in 1995.70 Similarly, haemophilic patients
previously have had high rates of infection with HBV and HCV. Virtually all patients
treated with CFC before 1985 were exposed to HCV.71 In one study of HIV-negative
adults, 5% had chronic HBV antigenaemia, 71% were seropositive for HBV, and 82%
were seropositive for HCV.72 25% of the deaths of HIV-infected patients were from liver
disease in 1997 to 1999.73
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Region and organisation

Website

UK
UK Haemophilia Alliance
UK Haemophilia Society
UK Haemophilia Centre Doctors’ Organisation
National Creutzfeldt-Jakob Disease Surveillance Unit

http://www.haemophiliaalliance.org.uk
http://www.haemophilia.org.uk
http://www.ukhcdo.org
http://www.cjd.ed.ac.uk

Canada
Association of Hemophilia Clinic Directors of Canada
Blood-Borne Pathogens Surveillance Project
Canadian Hemophilia Society
Blood-Borne Pathogen Surveillance Network

http://www.ahcdc.ca/
http://www.ahcdc.ca/bbps
http://www.hemophilia.ca/en/1.1.1.php
http://www.hc-sc.gc.ca/pphb-dgspsp/hcai-iamss/bpppts/sys_e.html

USA
US National Hemophilia Foundation
Regional Centers of Excellence for Biodefense and
Emerging Infectious Diseases
Centers for Disease Control and Prevention

http://www.hemophilia.org
http://www2.niaid.nih.gov/biodefense/research/rce.htm
http://www.cdc.gov

International
World Federation of Hemophilia

http://www.wfh.org

Table 1: Public-health resource organizations

These observations highlight an important clinical issue for the treatment of
haemophilic patients—that infections with several viruses complicate and confuse the
clinical picture. For example, among HIV-infected individuals, subsequent HBV infection
produces chronic disease in about 50% of cases, compared with 10% among HIVnegative patients.74 HIV infection of a patient chronically infected with HBV, however,
results in a higher degree of HBV replication. Nevertheless, these patients have milder
liver inflammation and less liver fibrosis than HIV-negative individuals because the
pathogenesis of chronic HBV infection is governed by immune-mediated mechanisms.
Treatment of the immunodeficiency in these patients can accelerate liver disease, so
antiretroviral therapy in patients infected with both HIV and HBV should include at least
one agent that is active against HBV.
Similar types of interactions have been observed between HIV and HCV.75 HIV infection
increases the rate of progression to liver cirrhosis and decreases the response to
interferon-based treatments.76,77 This last effect has complicated treatment
recommendations for these patients. If the immune system is well preserved (ie, the
CD4-cell count is high), treatment of the HCV infection first might be prudent. If the
patient has more advanced HIV disease, however, therapy for HIV should perhaps be
started before that for HCV. The effect of infection with HCV on HIV progression
remains uncertain; however, some studies suggest that patients infected with both
viruses have accelerated progression of HIV disease and a blunted response to
antiretroviral therapy.
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Therapeutic CFC: protection from emerging infectious agents
Replacement therapy has formed the cornerstone of haemophilia treatment for longer
than 100 years.78 At first, whole blood was the source of exogenous coagulation factors.
As treatment options evolved, whole blood was replaced with increasingly purified
plasma product fractions, such as fresh-frozen plasma and cryoprecipitate, culminating
in the high-purity, plasma-derived and recombinant products available now.
Since the available agents are highly effective, the choice of coagulation factor is driven
primarily by product safety and cost concerns. Ultimately, cost-benefit analyses are
needed to help physicians treating haemophilia to choose the best therapeutic option
rationally. There have been no conclusive studies, but any pharmacoeconomic model
will need to include some key principles. For example, because haemophilic patients
need repeated infusions throughout their lives, the cumulative risk of transfusiontransmitted infectious diseases increases over their lifetimes, although currently the
perceived overall threat is low. Furthermore, haemophilic patients are well informed
about their disorder, and they might be expected to demand safer products when they
hear about emerging infections. Given the complexities associated with choice of
coagulation factor, clinicians and funders must understand the safety properties of the
two main types of therapeutics, plasma-derived and recombinant coagulation factors.
Plasma-derived coagulation factors
Human plasma-derived CFC were one of the original products used in the treatment of
haemophilia. Each year, tens of thousands of patients receive plasma-derived
products.79 However, for longer than three decades, plasma-derived CFC have been
known to transmit infectious pathogens.80 Human plasma donations are therefore
routinely screened for known infectious agents by antigen, antibody, and nucleic-acid
testing procedures. Compared with whole blood or plasma, CFC have the additional
safety advantage of undergoing plasma fractionation and are subject to procedures to
reduce numbers of viruses during manufacture, including chromatographic
fractionation, nanofiltration, solvent detergent treatment, and heat inactivation. Thus,
plasma-derived coagulation factors now have a very low risk of transfusion-mediated
infection with HBV, HCV, HIV, and HTLV I and II. We emphasise, however, that none of
the current viral reduction steps in the manufacture of concentrates eliminate the risk of
transmission of nonlipid-coated viruses. Plasma-derived CFC have been widely available
for 30 years. They are effective at preventing and stopping haemorrhage in most
patients with haemophilia and have therefore revolutionised the lives of patients. Many
are able to treat themselves at home. With regular injections in childhood, most bleeds
can be prevented, allowing children to grow up with normal joints and not, as was
previously commonplace, crippled with arthritis.
Recombinant coagulation factors
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The threat from unknown emerging infectious agents has encouraged manufacturers to
remove dependency on pooled blood plasma entirely from the manufacturing process.
They have therefore developed methods for expressing human genes for coagulation
factors within immortalised tissue-culture cells. Subsequent immunoaffinity and columnchromatographic purification and viral inactivation and removal steps result in highly
purified therapeutic preparations that are fully active. These processes decrease the
likelihood of contamination by emerging infectious agents. There is a possibility,
however, that the cell line could be infected with, and propagate, a pathological prion.81
The first recombinant factor VIII concentrate was marketed in 1992 for the treatment
of haemophilia A. Other products followed (table 2).
Concentrate

Producing
Cell
Line

Factor VIII molecule

Addition of human or animal proteins to: Virus removal/
inactivation method
Cell culture/
Final

RecombinateBioclate*

CHO

Yes

Yes

Kogenate/Helixate*

BHK

Full-length; coexpressed
with VWF
Full-length

Yes

Yes

CHO

B-domain deleted

Yes

No

BHK BHK

Full-length

Yes

No

Advate

CHO

Full-length; coexpressed
with VWF

No

No

ReFacto AF†

CHO

B-domain deleted

No

No

purification

formulation

First generation
Immunoaffinity,
ion exchange
Immunoaffinity,
ion exchange,
ultrafiltration

Helixate*
Second generation
ReFacto

Kogenate FS/
Helixate FS

Immunoaffinity,
ion exchange,
solvent detergent,
nanofiltration
Immunoaffinity,
ion exchange,
solvent detergent,
ultrafiltration

Helixate FS
Third generation
Immunoaffinity,
ion exchange,
solvent detergent
Immunoaffinity,
ion exchange,
solvent detergent,
nanofiltration

VWF=von Willebrand factor. *No longer commercially available. †Not yet commercially available.

Table 2: Commercial recombinant factor VIII products

The first-generation recombinant concentrates were manufactured from cultures that
contained animal and human proteins. Human albumin was also added as an excipient
to the final preparation. In the second generation, protein stabilisers such as albumin
were replaced with sucrose to eliminate the potential of pathogen transmission.
Recombinant factor VIIa is also a second-generation product used to treat
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haemophiliacs who have antibodies to factor VIII and do not respond to factor VIII
concentrates.
In third-generation concentrates, the factor-VIII transfected cell line is grown in
medium without addition of any animal or human proteins.2 This approach has greatly
reduced the risk that could be posed by future emerging pathogens. The only licensed
recombinant factor IX concentrate, BeneFIX, is also a third-generation concentrate. To
improve safety in the manufacture of recombinant concentrates, all manufacturing
processes now include a virus-inactivation process, such as solvent detergent. In
addition, the monoclonal antibodies used to purify factor VIII from cell cultures are
made from hybridoma cell lines grown in the absence of added mammalian protein.
Although recombinant CFC are judged to be at lower risk of transmitting infectious
agents, concern has been expressed that they might be associated with a higher
incidence of alloantibody development in response to the transfused factor VIII.82
Future gene-transfer technologies might allow the preparation of human clotting-factor
proteins by novel and high-yielding processes that would enable the native protein to
be expressed.
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